How India Exports Rivaroxaban to the World

In the United States, rivaroxaban is marketed under the brand name Xarelto. The FDA has approved multiple Abbreviated New Drug Applications (ANDAs) for generic versions of rivaroxaban. For instance, on November 12, 2021, the FDA approved an ANDA for Rivaroxaban Tablets, 2.5 mg, submitted by Viatris Limited. Additionally, on June 10, 2024, the FDA approved a group of variations for Rivaroxaban Viatris, including changes in pack sizes. These approvals indicate a growing acceptance of generic rivaroxaban in the U.S. market. Notably, MYLAN LABORATORIES LIMITED, a leading exporter from India, has a significant presence in the U.S. market, reflecting the global reach of Indian pharmaceutical companies.

In the European Union, the European Medicines Agency (EMA) granted marketing authorization for Xarelto (rivaroxaban) on September 30, 2008. Subsequently, generic versions have been approved, such as Rivaroxaban Accord on November 16, 2020, and Rivaroxaban Viatris on November 12, 2021. The EMA has also provided product-specific bioequivalence guidance for rivaroxaban, effective January 1, 2026, to ensure consistent quality and efficacy among generics. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) for marketing authorization. The significant export volumes to the Netherlands and Malta underscore the importance of the EU market for Indian exporters.

Rivaroxaban is included in the 21st edition of the WHO Model List of Essential Medicines, highlighting its critical role in global health. While specific WHO Prequalification for rivaroxaban is not detailed, adherence to international pharmacopoeia standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is essential for market acceptance. Compliance with these standards ensures the quality and safety of rivaroxaban products in international markets.

In India, rivaroxaban is classified under Schedule H, indicating it is a prescription-only medication. The Drug Price Control Order (DPCO) and the National Pharmaceutical Pricing Authority (NPPA) regulate its pricing; however, specific ceiling prices are subject to periodic revisions. Export of rivaroxaban requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patents for rivaroxaban have expired, allowing for the introduction of generic versions. This has led to increased competition among manufacturers, including Indian exporters, contributing to the substantial export figures and the presence of multiple active exporters in the market.

In July 2025, the EMA adopted revised bioequivalence guidance for rivaroxaban, effective January 1, 2026, to ensure uniform standards for generic formulations. In September 2025, the EMA approved Rivaroxaban Koanaa, a generic version, expanding the availability of rivaroxaban in the EU market. In November 2025, the EMA updated the product information for Rivaroxaban Viatris, reflecting ongoing regulatory oversight. In June 2024, the FDA approved a group of variations for Rivaroxaban Viatris, including changes in pack sizes, indicating continuous regulatory engagement. In November 2023, the EMA adopted a positive opinion recommending changes to the marketing authorization for Pradaxa, another anticoagulant, reflecting the dynamic nature of the anticoagulant market.

These developments underscore the evolving regulatory landscape for rivaroxaban, with Indian exporters playing a pivotal role in supplying global markets.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), with approximately 70% of KSMs imported from China as of 2023. This dependency exposes the supply chain to risks associated with geopolitical tensions and regulatory changes in China. For instance, in 2018, environmental regulations in China led to the shutdown of numerous chemical plants, causing significant disruptions in the supply of KSMs and subsequent price increases for APIs.

The COVID-19 pandemic further highlighted these vulnerabilities, as lockdowns and export restrictions in China during early 2020 disrupted the supply of essential raw materials, leading to production delays and increased costs for Indian pharmaceutical manufacturers. Such events underscore the critical need for India to develop domestic capabilities in KSM and API production to mitigate future supply chain risks.

The export market for Rivaroxaban is notably concentrated, with the top five exporters accounting for 58.8% of total exports. MYLAN LABORATORIES LIMITED alone holds a 32.3% share, indicating a significant reliance on a limited number of suppliers. This concentration poses a risk of supply disruptions if any of these key exporters face operational challenges.

To address such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and reduce dependence on imports. The scheme has led to increased investments in API production facilities, with commitments exceeding ₹4,570 crore by 2025. However, the effectiveness of the PLI scheme in diversifying the supplier base for Rivaroxaban remains to be fully realized.

Recent geopolitical tensions and maritime disruptions have significantly impacted global shipping routes, affecting pharmaceutical exports from India. In early 2026, conflicts in the Red Sea and the Strait of Hormuz led to the rerouting of vessels and increased transit times. These disruptions resulted in a doubling of freight charges and surcharges ranging from $4,000 to $8,000 per shipment, placing additional financial strain on exporters.

Furthermore, the ongoing trade tensions between the United States and China have introduced uncertainties in the global supply chain, potentially affecting the availability and cost of raw materials necessary for Rivaroxaban production. While no specific shortage alerts for Rivaroxaban have been issued by the FDA or EMA as of March 2026, the industry remains vigilant to potential disruptions.

• Diversify Raw Material Sources: Encourage the development of domestic KSM and API production facilities to reduce reliance on imports, particularly from China.

• Expand Supplier Base: Identify and qualify additional manufacturers for Rivaroxaban to mitigate risks associated with supplier concentration.

• Enhance Supply Chain Resilience: Invest in advanced logistics and inventory management systems to better respond to shipping disruptions and geopolitical events.

• Monitor Regulatory Developments: Stay informed about international regulatory changes that may impact raw material availability and compliance requirements.

• Leverage Government Initiatives: Participate actively in government schemes like the PLI to strengthen domestic manufacturing capabilities and reduce import dependency.

RISK_LEVEL: MEDIUM